We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $529M
1-Year Est. Return 337.4%
This Fund
S&P 500
This Quarter Est. Return
+27.32%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$529M
AUM Growth
+$94M
Cap. Flow
-$41.6M
Cap. Flow %
-7.87%
Top 10 Hldgs %
51.64%
Holding
54
New
12
Increased
7
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$23.1M
2
VERA icon
Vera Therapeutics
VERA
+$15M
3
SGMT icon
Sagimet Biosciences
SGMT
+$13.8M
4
DFTX
Definium Therapeutics
DFTX
+$10.5M
5
IMMX icon
Immix Biopharma
IMMX
+$8.61M

Top Sells

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$31.5M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$16.2M
3
KALV
KalVista Pharmaceuticals
KALV
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$13.6M
5
JBIO
Jade Biosciences
JBIO
+$13.6M

Sector Composition

Rank Sector Weight
1 Healthcare 78.18%
2 Miscellaneous 19.78%
3 Financials 2.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
26
Relmada Therapeutics
RLMD
$434M
$5.83M 1.1%
842,106
– –
JATT
27
JATT II Acquisition Corp
JATT
$96.4M
$5.68M 1.07%
+500,000
New +$5.31M
CGEM icon
28
Cullinan Oncology
CGEM
$1.35B
$5.46M 1.03%
300,000
– –
ALT icon
29
Altimmune
ALT
$640M
$5.29M 1%
+1,741,232
New +$5.2M
AMAN
30
Amanat Acquisition Corp
AMAN
$104M
$5.08M 0.96%
+500,000
New +$5.05M
RZLT icon
31
Rezolute
RZLT
$402M
$4.95M 0.94%
951,809
– –
SLN
32
Silence Therapeutics
SLN
$827M
$4.94M 0.93%
450,000
-570,489
-56% -$4.01M
PALI icon
33
Palisade Bio
PALI
$350M
$4.78M 0.9%
2,284,819
-1,120,938
-33% -$2.21M
EVMN
34
Evommune Inc
EVMN
$383M
$4.32M 0.82%
325,000
– –
SCYX icon
35
SCYNEXIS
SCYX
$46.8M
$3.84M 0.73%
944,292
-1
-0% -$6
GALT icon
36
CALL
Galectin Therapeutics
GALT
$393M
$3.71M 0.7%
800,000
– –
ELVN icon
37
Enliven Therapeutics
ELVN
$4.12B
$3.55M 0.67%
+70,000
New +$2.97M
HUMA icon
38
Humacyte
HUMA
$158M
$2.93M 0.55%
3,750,000
– –
RNTX
39
Rein Therapeutics
RNTX
$67.4M
$2.68M 0.51%
+2,575,000
New +$3.12M
DBVT
40
DBV Technologies
DBVT
$815M
$2.57M 0.49%
+156,906
New +$2.96M
AVXL icon
41
CALL
Anavex Life Sciences
AVXL
$247M
$1.35M 0.26%
521,300
– –
PMN icon
42
ProMIS Neurosciences
PMN
$120M
$1.13M 0.21%
86,150
-285,252
-77% -$3.1M
ALKS icon
43
Alkermes
ALKS
$7.74B
– –
-50,000
Closed -$1.77M
APGE
44
DELISTED
Apogee Therapeutics
APGE
– –
-374,000
Closed -$31.5M
JBIO
45
Jade Biosciences
JBIO
$1.22B
– –
-964,462
Closed -$13.6M
AVTX icon
46
Avalo Therapeutics
AVTX
$921M
– –
-124,666
Closed -$1.86M
CMPX icon
47
Compass Therapeutics
CMPX
$369M
– –
-1,350,000
Closed -$7.14M
CNTX icon
48
Context Therapeutics
CNTX
$33.7M
– –
-2,238,496
Closed -$5.86M
IMVT icon
49
Immunovant
IMVT
$7.87B
– –
-545,625
Closed -$13.6M
KALV
50
DELISTED
KalVista Pharmaceuticals
KALV
– –
-675,000
Closed -$13.6M
1
2
3

Similar funds

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
FFIC
First Fiduciary Investment Counsel Cleveland, Ohio $529M AUM 15.02% 1-Year Est. Return
TA
Teramo Advisors Naples, Florida $529M AUM 20.59% 1-Year Est. Return
JDLA
J. Derek Lewis & Associates Newport Beach, California $529M AUM
CCG
Clearlake Capital Group Santa Monica, California $529M AUM 50.26% 1-Year Est. Return
DAS
DMKC Advisory Services Des Moines, Iowa $530M AUM 22.27% 1-Year Est. Return
VAMG
Voisard Asset Management Group Grand Rapids, Michigan $529M AUM 21.43% 1-Year Est. Return
CWM
Compass Wealth Management Guilford, Connecticut $528M AUM 40.26% 1-Year Est. Return

Great Point Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Great Point Partners held 54 positions worth $529M, up 22% from $435M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners withdrew a net $41.6M in Q2 2026, closing 12 positions and reducing 10 holdings. Its most notable exit was Apogee Therapeutics, an estimated $31.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Great Point Partners opened a new position in Abivax worth $27.2M.

  • Great Point Partners's largest Q2 2026 buy was Abivax: 204,314 shares worth $27.2M.
  • Great Point Partners added most to Vera Therapeutics in Q2 2026, an estimated $15M increase.
  • Great Point Partners's biggest Q2 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $16.2M.
  • Great Point Partners fully exited Apogee Therapeutics in Q2 2026, selling an estimated $31.5M.
  • Great Point Partners's ten largest holdings make up 52% of its $529M portfolio in Q2 2026.
  • Great Point Partners opened 12 new positions and closed 12 in Q2 2026.
  • Great Point Partners's portfolio value rose 22% quarter-over-quarter to $529M.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.